Ashdod, Israel

Madelene Mimon

This inventor holds 1 USPTO granted patent. Top assignee: Insight Strategy Marketing Ltd.. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 18(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Madelene Mimon

Introduction

Madelene Mimon is a notable inventor based in Ashdod, Israel. He has made significant contributions to the field of biotechnology, particularly in the development of genetically modified cells. His work focuses on enhancing the expression and purification of recombinant heparanase, a crucial enzyme in various biological processes.

Latest Patents

Mimon holds a patent for "Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same." This patent encompasses bacterial, yeast, and animal cells, along with methods for overexpressing recombinant heparanase in cellular systems. It also details methods of purifying recombinant heparanase and modified heparanase species that serve as precursors for generating highly active heparanase through proteolysis. He has 1 patent to his name.

Career Highlights

Madelene Mimon is associated with Insight Strategy & Marketing Ltd., where he applies his expertise in biotechnology. His innovative approaches have positioned him as a key figure in his field, contributing to advancements in medical and therapeutic applications.

Collaborations

Mimon has collaborated with notable colleagues, including Maty Ayal-Hershkovitz and Haim Moskowitz. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Madelene Mimon's work in biotechnology exemplifies the impact of innovative thinking in the scientific community. His contributions to the understanding and application of recombinant heparanase are paving the way for future advancements in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…